Salud por Derecho, together with organisations from Morocco, Tunisia and Ukraine, has filed third-party observations at the European Patent Office against a Gilead patent application covering the combination of lenacapavir and islatravir. Gilead and Merck are jointly developing a treatment that combines both drugs in a single once-weekly pill for HIV treatment. If approved, it would be the first once-weekly oral HIV treatment.
This is our second joint filing in six weeks. At the end of September, we called on the European Patent Office to reject a Merck application on alimatravir, an investigational once-monthly oral medicine for HIV prevention. We are now taking action at the Office again, this time against Gilead’s application.
The new observations were filed on 6 November together with ITPC MENA, ATL MST-SIDA and 100% Life. This procedure allows organisations that are not parties to the proceedings to explain why they believe an application should not be granted a patent before the Office makes its decision.
A once-weekly pill
Gilead and Merck are developing a single tablet combining lenacapavir and islatravir. If approved, it would allow people to move from a daily oral treatment to a single dose once a week. The Phase 3 ISLEND-1 and ISLEND-2 trials followed people living with HIV for 48 weeks after they switched from their daily regimen to the new combination. Participants maintained viral suppression. If authorised by regulatory agencies, it would become the first once-weekly oral HIV treatment.
Taking one pill a week could make treatment easier to follow, offer greater discretion and remove one daily reminder of a person’s HIV status. We are not questioning that potential benefit. What we challenge is whether the combination warrants a new patent.
Why we are challenging the patent
The organisations consider that the application lacks inventive step. Before Gilead filed it, published documents had already proposed combining these types of medicines, and islatravir had already been presented as a suitable option for long-acting treatment.
The observations also point out that the application contains no experimental data on the combination. In the coalition’s view, combining the two medicines was an option that a person skilled in the field could have inferred from the knowledge already available.
“Scientific progress in HIV treatment must translate into real access for people everywhere, not into new barriers created by unjustified patents. The European Patent Office has a responsibility to protect the public interest. Decisions made in Europe have consequences far beyond its borders and must not stand in the way of affordable generic medicines. Innovation must serve public health, not prolong monopolies,” says Vanessa López, Executive Director of Salud por Derecho.
Why the decision affects Morocco
Gilead has requested that the patent take effect in Morocco. If the European Patent Office grants it, the patent may be validated in the country once the national formalities have been completed, without the Moroccan office carrying out a fresh substantive examination of whether the combination meets the requirements for patent protection.
Moroccan organisations explain that there is also no national administrative procedure through which the patent could be opposed after it is granted.
“This patent would take effect in Morocco without having been examined in the country and, once granted, the only way to challenge it would be through a long and costly court case. The European Patent Office is now the place where we can still defend our public health interests. A once-weekly pill could change the daily lives of people living with HIV and should not be blocked by a patent on a combination that was already obvious,” explains Othmane Marrakchi, Advocacy Officer at ITPC MENA.
For prevention, Morocco will have access to generic lenacapavir at $40 per person per year from 2027, thanks to an agreement backed by Unitaid. For treatment, the picture could be very different. No voluntary licence covers the lenacapavir-islatravir combination and, if this patent is granted, it could keep generics out of Morocco until 2037.
The previous application on alimatravir designated Georgia, Cambodia, Morocco, Moldova and Tunisia as validation states. The new application directly affects Morocco. In both cases, a decision taken in Munich could weigh on access to medicines in countries that have no say in their examination.
“For people living with HIV in Tunisia, access to treatment is not an abstract debate about patents. It is a question of dignity, quality of life and the right to live without unnecessary barriers. A once-weekly treatment could bring real improvements to people’s daily lives, but innovation has no value if it remains out of reach. People living with HIV must be recognised as rights-holders and active participants in the decisions that affect their lives. Nothing about us without us,” says Kods Brahmi, Advocacy Officer at ATL MST-SIDA.




